| Latest Astrazeneca News Headlines |
| Date | Time | Source | |
| 11/20/2008 | 9:20AM | PRNUS | Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
DALLAS, Nov. 20 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), Pfizer Inc... More...>> |
| 11/19/2008 | 11:21AM | PRNUS | Seven Summits Research Releases Comments on MS, MRK, UNP, AZN, and AG
CHICAGO, Nov. 19 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/1119X (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 11/18/2008 | 10:00AM | PRNUS | AstraZeneca Appoints Rich Fante as President of its U.S. Business
WILMINGTON, Del., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced the appointment of Rich Fante as President of the company's U.S. business.
Fante takes over from Tony Zook, whose role was expanded after recently being named President of MedImmune, the wholly owned biologics business for AstraZeneca... More...>> |
| 11/12/2008 | 8:00AM | PRNUS | Survey Shows Lung Cancer Patients Blamed for Their Diagnosis
As public support decreases, so do research dollars and patient hope
WASHINGTON, Nov. 12 /PRNewswire-FirstCall/ -- Survey results released today show that the general population blames lung cancer patients for their diagnosis, confirming the stigma that patients reportedly feel. Findings also demonstrate a lack of... More...>> |
| 11/09/2008 | 9:00AM | PRNUS | CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
NEW ORLEANS, Nov. 9 /PRNewswire-FirstCall/ -- New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for... More...>> |
| 11/05/2008 | 11:01AM | PRNUS | Seven Summits Research Releases Comments on AMZN, GM, SNDK, AZN, and GWW
CHICAGO, Nov. 5 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/1105X (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 10/15/2008 | 9:46AM | PRNUS | AstraZeneca and Columbia University Medical Center Sign Strategic Research Collaboration in Neurosciences; Focus on New Approach
WILMINGTON, Del. and NEW YORK, Oct. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) and Columbia University Medical Center today announced a new research collaboration to examine how neurogenesis -- the creation of new neuronal cells - in adults might offer novel approaches to treating depression and anxiety.
For... More...>> |
| 10/13/2008 | 9:03AM | PRNUS | AstraZeneca Survey: Physicians Play Critical Role in Helping Patients Take Medicines as Prescribed
WILMINGTON, Del., Oct. 13 /PRNewswire-FirstCall/ -- Affordability concerns and the perceived lack of need for a medicine are the top reasons why patients do not take their medicines as prescribed, according to a recent AstraZeneca (NYSE:AZN) survey of more than 200 office-based physicians.
The physicians ranked the... More...>> |
| 10/10/2008 | 8:00AM | PRNUS | FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
WILMINGTON, Del., Oct. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR(R) (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic... More...>> |
| 09/29/2008 | 6:22PM | PRNUS | Hagens Berman Sobol Shapiro: Judge Approves Two National Classes in AWP Drug Litigation
AstraZeneca and Bristol-Myers Squibb face separate trials for alleged unfair and deceptive practices relating to cancer fighting drugs.
BOSTON, Sept. 29 /PRNewswire/ -- Two major pharmaceutical companies are facing the fire this week after U.S. District Judge Patti Saris approved two national classes in the Average... More...>> |
| 09/23/2008 | 1:28PM | PRNUS | AstraZeneca Recognized as One of Working Mother Magazine's '100 Best Companies'
WILMINGTON, Del., Sept. 23 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN), a global leader in the pharmaceutical industry, has been named one of the "100 Best Companies" to work for by Working Mother magazine for the seventh consecutive year. This honor recognizes the company's commitment to family-friendly policies... More...>> |
| 09/15/2008 | 5:00PM | PRNUS | AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease
WILMINGTON, Del., Sept. 15 /PRNewswire-FirstCall/ --
-- Results inconclusive, as primary outcome measure not statistically
significant for either donepezil or AZD3480; results impacted by
improvement in placebo group
-- Improvements shown on secondary outcome measures ADCS-CGIC and MMSE
-- Overall... More...>> |
| 08/15/2008 | 2:30AM | PRNUS | AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
SINGAPORE, Aug. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced an innovative new partnership with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds. The collaboration, which is spelt out in a Memorandum of Understanding (MOU... More...>> |
| 08/14/2008 | 8:00AM | PRNUS | Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
ABBOTT PARK, Ill. and WILMINGTON, Del., Aug. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and AstraZeneca (NYSE:AZN) announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR(R) (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.
Under the... More...>> |
| 07/23/2008 | 8:00AM | PRNUS | AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs
WILMINGTON, Del., July 23 /PRNewswire-FirstCall/ -- More than a third of the people who contacted AstraZeneca (NYSE:AZN) to inquire about the company's prescription savings programs learned of the programs from their doctors or pharmacists, according to a year-long survey of more than 12,000 patients.
The survey found... More...>> |
| 07/10/2008 | 7:45AM | PRNUS | AstraZeneca Supports New PhRMA Code on Interactions with Healthcare Providers: Will Ensure Compliance to Benefit Patient Care
WILMINGTON, Del., July 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) announced today that it fully supports PhRMA's revised code guiding the pharmaceutical industry's interactions with healthcare providers, including new guidelines on promotional items, meals and sponsorship of meetings.
The company is taking... More...>> |
| 07/01/2008 | 6:28PM | PRNUS | Summary Judgment Granted for SEROQUEL(R) Patent Litigation
WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement... More...>> |
| 06/04/2008 | 8:00AM | PRNUS | AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
WILMINGTON, Del., June 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the... More...>> |
| 05/30/2008 | 7:00AM | PRNUS | AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
WILMINGTON, Del., May 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) I.V. (esomeprazole sodium) for Injection to seek approval for use in patients with peptic ulcer bleeding... More...>> |
| 05/22/2008 | 12:13PM | PRNUS | AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
WILMINGTON, Del., May 22 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) announced today that it supports the revised Physician Payment Sunshine Act as part of the company's latest step to provide the public with more information about the way it does business.
Sponsored by Sens. Charles Grassley of Iowa and Herb... More...>> |